Skip to Content

Eletriptan Pregnancy and Breastfeeding Warnings

Eletriptan is also known as: Relpax

Eletriptan Pregnancy Warnings

Animal studies in rats and rabbits have revealed evidence of developmental toxicity (e.g., decreased fetal weight, increased incidence of minor vertebral alterations, delayed ossification) at exposure levels 6 to 12 times greater than the clinical maximum recommended daily dose of 80 mg. There are no controlled data in human pregnancy. AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. AU TGA pregnancy category: B1 US FDA pregnancy category: C

See references

Eletriptan Breastfeeding Warnings

Use with caution Excreted into human milk: Yes Comment: Infant exposure can be minimized by avoiding breastfeeding for 24 hours after treatment.

Following a single 80 mg dose, mean excretion in breast milk over 24 hours (n=8) was approximately 0.02% of administered dose. The concentration of the active metabolite was not measured (its serotonin agonist activity is 10% of parent drug). For infants older than 2 months, adverse effects are not expected.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals, New York, NY.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals, New York, NY.
  4. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.